Literature DB >> 1437564

The basic RNA-binding domain of HIV-2 Tat contributes to preferential trans-activation of a TAR2-containing LTR.

Y N Chang1, K T Jeang.   

Abstract

Human immunodeficiency viruses HIV-1 and HIV-2 encode a Tat protein that trans-activates the respective viral genome through RNA targets (TAR1 and TAR2). Tat-1 and Tat-2 have considerable homology. However, an interesting biological observation has been that Tat-1 activates the HIV-1 and HIV-2 LTRs equally while Tat-2 activates the former, in comparison to the latter, poorly. Here, we present evidence that it is the TAR2 RNA target together with the basic RNA-binding protein domain of Tat-2 that dictate this non-reciprocity in trans-activation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1437564      PMCID: PMC334357          DOI: 10.1093/nar/20.20.5465

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  33 in total

1.  The trans-activator gene of the human T cell lymphotropic virus type III is required for replication.

Authors:  A I Dayton; J G Sodroski; C A Rosen; W C Goh; W A Haseltine
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

2.  Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein.

Authors:  C Southgate; M L Zapp; M R Green
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

3.  The acidic amino-terminal region of the HIV-1 Tat protein constitutes an essential activating domain.

Authors:  J Rappaport; S J Lee; K Khalili; F Wong-Staal
Journal:  New Biol       Date:  1989-10

4.  Tat trans-activates the human immunodeficiency virus through a nascent RNA target.

Authors:  B Berkhout; R H Silverman; K T Jeang
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

5.  A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation.

Authors:  S Roy; U Delling; C H Chen; C A Rosen; N Sonenberg
Journal:  Genes Dev       Date:  1990-08       Impact factor: 11.361

6.  trans activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: a quantitative analysis.

Authors:  B Berkhout; K T Jeang
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

7.  Mutational analysis of the conserved cysteine-rich region of the human immunodeficiency virus type 1 Tat protein.

Authors:  A P Rice; F Carlotti
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

8.  Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis.

Authors:  M Kuppuswamy; T Subramanian; A Srinivasan; G Chinnadurai
Journal:  Nucleic Acids Res       Date:  1989-05-11       Impact factor: 16.971

9.  Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120.

Authors:  C Cheng-Mayer; T Shioda; J A Levy
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

10.  Sp1-dependent activation of a synthetic promoter by human immunodeficiency virus type 1 Tat protein.

Authors:  J Kamine; T Subramanian; G Chinnadurai
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

View more
  13 in total

1.  TAR RNA binding properties and relative transactivation activities of human immunodeficiency virus type 1 and 2 Tat proteins.

Authors:  H Rhim; A P Rice
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

2.  Exon2 of HIV-2 Tat contributes to transactivation of the HIV-2 LTR by increasing binding affinity to HIV-2 TAR RNA.

Authors:  H Rhim; A P Rice
Journal:  Nucleic Acids Res       Date:  1994-10-25       Impact factor: 16.971

3.  Exchange of the basic domain of human immunodeficiency virus type 1 Rev for a polyarginine stretch expands the RNA binding specificity, and a minimal arginine cluster is required for optimal RRE RNA binding affinity, nuclear accumulation, and trans-activation.

Authors:  Y S Nam; A Petrovic; K S Jeong; S Venkatesan
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy.

Authors:  C M Browning; L Cagnon; P D Good; J Rossi; D R Engelke; D M Markovitz
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  Modulation of Sp1 phosphorylation by human immunodeficiency virus type 1 Tat.

Authors:  R F Chun; O J Semmes; C Neuveut; K T Jeang
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

6.  Modifications in host cell cytoskeleton structure and function mediated by intracellular HIV-1 Tat protein are greatly dependent on the second coding exon.

Authors:  M R López-Huertas; S Callejas; D Abia; E Mateos; A Dopazo; J Alcamí; M Coiras
Journal:  Nucleic Acids Res       Date:  2010-02-05       Impact factor: 16.971

7.  Inhibition of HIV-1 expression by HIV-2.

Authors:  J Rappaport; S K Arya; M W Richardson; G Baier-Bitterlich; P E Klotman
Journal:  J Mol Med (Berl)       Date:  1995-12       Impact factor: 4.599

8.  Relatedness of an RNA-binding motif in human immunodeficiency virus type 1 TAR RNA-binding protein TRBP to human P1/dsI kinase and Drosophila staufen.

Authors:  A Gatignol; C Buckler; K T Jeang
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

9.  Direct interactions between autoantigen La and human immunodeficiency virus leader RNA.

Authors:  Y N Chang; D J Kenan; J D Keene; A Gatignol; K T Jeang
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

10.  Inhibitory Effects of HIV-2 Vpx on Replication of HIV-1.

Authors:  Mohamed Mahdi; Zsófia Szojka; János András Mótyán; József Tőzsér
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.